Approximately 400,000 people in Poland suffer from schizophrenia. Approx. 32% of patients in psychiatric hospitals are people with this diagnosis. This article presents facts about this disease, as well as new hopes related to the market introduction of the first second-generation, prolonged-acting antipsychotic drug containing risperidone.